Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.94 USD
+0.04 (1.03%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $3.94 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
Repare Therapeutics Inc. (RPTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.67 | $25.00 | $8.00 | 276.15% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Repare Therapeutics Inc. comes to $14.67. The forecasts range from a low of $8.00 to a high of $25.00. The average price target represents an increase of 276.15% from the last closing price of $3.90.
Analyst Price Targets (6 )
Broker Rating
Repare Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 85.71%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/16/2024 | Capital One Securities | Timothy Chiang | Strong Buy | Strong Buy |
5/7/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
4/19/2024 | Bloom Burton & Company | David Martin | Moderate Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
3/8/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
2/13/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 7 |
Average Target Price | $14.67 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -0.85 |